Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;44(5):425-436.
doi: 10.1007/s10928-017-9529-x. Epub 2017 Jun 16.

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease

Chuanpu Hu  1 , Omoniyi J Adedokun  2 , Yang Chen  2 , Philippe O Szapary  3 , Christopher Gasink  3 , Amarnath Sharma  2 , Honghui Zhou  2
Affiliations

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease

Chuanpu Hu et al. J Pharmacokinet Pharmacodyn. 2017 Oct.

Abstract

Informative exposure-response modeling of clinical endpoints is important in drug development to identify optimum dose and dosing regimens. Despite much recent progress in mechanism-based longitudinal modeling of clinical data, challenges remain in clinical trials of diseases such as Crohn's disease, where a commonly used composite endpoint Crohn's Disease Activity Index (CDAI) has considerable variation in its administration and scoring between different assessors and complex study designs typically include maintenance phases with randomized withdrawal re-randomizations and other response driven dose adjustments. This manuscript illustrates the complexities of exposure-response modeling of such composite endpoint data through a latent-variable based Indirect Response model framework for CDAI scores using data from three phase III trials of ustekinumab in patients with moderate-to-severe Crohn's Disease. Visual predictive check was used to evaluate model performance. Potential impacts of the study design on model development and evaluation of the E-R relationship in the induction and maintenance phases of treatment are discussed. Certain biases appeared difficult to overcome, and an autocorrelated residual error model was found to provide improvement.

Keywords: Autocorrelation; NONMEM; Population pharmacokinetic/pharmacodynamic modeling; Ustekinumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):322-330 - PubMed
    1. AAPS J. 2016 Jan;18(1):64-91 - PubMed
    1. N Engl J Med. 2012 Oct 18;367(16):1519-28 - PubMed
    1. J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):237-60 - PubMed
    1. J Clin Pharmacol. 2010 Mar;50(3):257-67 - PubMed

LinkOut - more resources